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Background: Probucol and statin are often prescribed for treating atherosclerosis. These two drugs exhibit different
mechanisms but it is unknown whether they have the same anti-atherogenic properties. In the current study, we
examined whether these two drugs at optimal doses could inhibit the initiation of atherosclerosis in cholesterol-fed
rabbits in the same way.
Methods: New Zealand White rabbits were fed a cholesterol-rich diet for 5 weeks to produce the early-stage lesions
of atherosclerosis. Drug-treated rabbits were administered either probucol or atorvastatin and serum lipids and
aortic atherosclerotic lesions were compared with those in a control group.
Results: Atorvastatin treatment significantly reduced serum total cholesterol levels while probucol treatment led
to significant reduction of high-density lipoprotein cholesterol levels without changing total cholesterol levels
compared with those in the control group. Compared with the control, probucol treatment led to 65% (p < 0.01)
reduction while atorvastatin treatment led to 23% (p = 0.426) reduction of the aortic lesion area. Histological and
immunohistochemical analyses revealed that the lesions of the probucol-treated group were characterized by
remarkable reduction of monocyte adherence to endothelial cells and macrophage accumulation in the intima
compared with those of both atorvastatin and control groups. Furthermore, low-density lipoprotein (LDL) isolated
from the probucol group exhibited prominent anti-oxidative reaction, which was not present in LDL isolated from
either the atorvastatin-treated or the control group.
Conclusions: This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte
adherence and infiltration into the subintima. Anti-oxidization of LDL by probucol protects more effectively against
early-stage lesion formation than statin-mediated lipid-lowering effects.
Keywords: Atherosclerosis, Monocyte, Probucol, Atorvastatin, HypercholesterolemiaBackground
Atherosclerosis is a chronic inflammatory disease that is
initiated by monocyte adhesion to arterial intimal sur-
faces followed by migration into the subintimal space.
Intimal monocytes are further differentiated into macro-
phages and then transformed into foam cells after
ingesting deposited lipids. High levels of plasma low-
density lipoprotein (LDL), especially oxidized LDL, are
the major atherogenic factor for the recruitment of
monocyte adhesion and induction of foam cell formation* Correspondence: jianglin@yamanashi.ac.jp
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stated.[1,2]. Therefore, reducing plasma LDL levels and inhib-
ition of LDL oxidization are the primary targets for the
prevention and treatment of atherosclerotic disease.
Probucol is not only a lipid-lowering drug but also has
anti-oxidant activity [3]. For this reason, it is often pre-
scribed for the treatment of hypercholesterolemia and
xanthoma. Probucol reduces plasma LDL-cholesterol
through increasing LDL catabolism and bile synthesis in
the liver [4,5]. However, in addition to LDL-cholesterol
lowering effects, probucol also simultaneously reduces
plasma high-density lipoprotein (HDL) levels. In the
past, low levels of plasma HDL-cholesterol (HDL-C) in-
duced by probucol were considered as a notorious side
effect, but now it is clear that the functions of HDLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication

















































Figure 1 Serum concentrations of total cholesterol (TC),
HDL-cholesterol (HDL-C), and triglycerides (TG). Data are
expressed as mean ± SEM (n = 8, each group). *P < 0.05,
**P < 0.01, ***P < 0.001 vs. vehicle.
Niimi et al. Lipids in Health and Disease 2013, 12:166 Page 2 of 8
http://www.lipidworld.com/content/12/1/166particles such as reverse cholesterol transport [6-8] and
scavenger receptor class B type I activity are actually up-
regulated [9,10]. Previous studies showed that probucol
treatment protects against atherosclerosis in WHHL and
cholesterol-fed rabbits [11,12]. Clinically, probucol has
been widely used in Asia, such as Japan, China, and
Korea, for the treatment of hyperlipidemia and athero-
sclerosis. Recently, a clinical trial demonstrated that
long-term probucol treatment reduced the risk of car-
diovascular events in familial hypercholesterolemia [13].
In spite of this, the lipid-lowering effect of probucol is
rather moderate compared with that of statins, hydroxy-
methylglutaryl (HMG)-CoA reductase inhibitors, the
most popular lipid-lowering drugs for the treatment of
hyperlipidemia. Statins reduce cholesterol biosynthesis
through inhibiting HMG-CoA reductase activity and in-
crease hepatic LDL receptor activity [14]. Furthermore,
statins also have anti-inflammatory effects designated as
pleiotropic effects. Nevertheless, treatment with statin
therapy alone can lead to only 30% reduction of the inci-
dence of coronary events [15,16]. Therefore, other non-
statin therapies are required for many patients who are
not responsive to statins [2,17].
In the current study, we compared these two drugs in
terms of atheroprotective effects in cholesterol-fed rabbits.
We were particularly interested in the initiation of athero-
sclerosis and made a side-to-side comparison of these two
drugs. Our results suggested that the anti-oxidative effects
exerted by probucol may be more beneficial for the inhib-
ition of monocyte adhesion and infiltration during athero-
genesis than statin-mediated cholesterol lowering effects.
Results
Serum lipids and lipoprotein profile
As shown in Figure 1, the average total cholesterol (TC)
level at the baseline (1 week) was 700 mg/dL after chol-
esterol diet feeding for 1 week. Serum TC level of the
vehicle group was increased to 1500 mg/dL at 5 weeks.
Atorvastatin treatment led to a significant reduction of
serum TC level at 3 and 5 weeks but did not change
HDL-C and triglyceride (TG) levels. Probucol treatment
did not affect TC and TG levels but significantly reduced
HDL-C level at 3 and 5 weeks. Analysis of lipoprotein
profiles by high performance liquid chromatography
(HPLC) revealed that the increased serum TC level was
essentially caused by elevated serum very-low-density
lipoprotein and LDL fractions in cholesterol-fed rabbits
and these fractions were markedly reduced in the
atorvastatin-treated group while HDL fractions were re-
duced in the probucol-treated group (Figure 2).
Aortic atherosclerosis
Analysis of en face aortic lesion area revealed that, al-
though both drug treatments inhibited the lesion size(65%↓ in the probucol group and 23%↓ in the atorva-
statin group compared with that in the vehicle group),
statistical significance was only found in probucol-
treated group (Figure 3, left). Histological examinations
showed that the aortic lesions were mainly composed of
infiltrating macrophages (Figure 3, right). Compared
with the vehicle group, intimal lesion area was remark-
ably reduced in the probucol group (92%↓ in aortic arch
and 95%↓ in thoracic aorta). The atorvastatin group also


































Figure 2 Analysis of serum lipoprotein profile by HPLC gel
filtration. Serum lipoproteins were fractionated using a gel filtration
column with on-line post-column cholesterol detection. Serum
lipoprotein profiles of normal rabbits fed a chow diet and cholesterol-
enriched for 5 weeks after drug treatment for 4 weeks. Data




















Figure 3 Analysis of aortic atherosclerosis. Representative photographs
the aortic atherosclerotic lesions on the surface was quantified using an im
aortic arch from each group (right, top). Serial frozen sections of aortas we
immunohistochemically stained with mAb against macrophages (Mϕ). Intim
Mϕ-positive area (right, bottom) were quantified with an image analysis sy
*P < 0.05, **P < 0.01 vs. vehicle.
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aorta, p > 0.05). Immunohistochemical staining showed
that the reduced lesion areas found in both drug-treated
groups were mainly caused by reduced macrophage infil-
tration: 96%↓ in aortic arch and 94%↓ in thoracic aorta
in the probucol group, and 51%↓ in aortic arch and
15%↓ in thoracic aorta in the atorvastatin group com-
pared with those in the control group, while a significant
difference was only found in the probucol group.
Scanning electron microscopic observation
We also examined the aortic surface changes by scanning
electron microscopy and observed monocyte-endothelial
interactions. Under the scanning electron microscopy, the
lesions of the aorta were visible even at low magnification.
While there was variation in lesion features from place to
place in the three groups, the number of monocytes ad-
hered to endothelial cells was generally less in the probu-
col group than in the atorvastatin or control group
(Figure 4), which was consistent with the observations in
light microscopic histological study described above. At
high magnification, there were diverse features of intimal
lesions (Figure 5): some areas appeared as raised ridges or












































of pinned-out aortic arch from each group (left, top). Scatter plot of
age analysis system (left, bottom). Representative micrographs of the
re stained with hematoxylin-eosin (HE), elastica van Gieson (EVG), or
al microscopic lesions on EVG-stained sections (right, middle) and












Figure 4 Representative micrographs of the aortic arch from each group observed under a scanning electron microscope. At low
magnification, monocytes that adhered to the intimal surface of the aorta in the probucol group are small in number compared with those in
the atorvastatin and control groups (left). Many monocytes are clearly visible in the atorvastatin and control groups at high magnification (right).
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endothelial surface either singly or in clusters. The bulged
or protuberant areas contained many monocytes beneath
endothelial cells, which can be observed in the areas
where endothelial cells were detached or split. These le-
sions were also fewer in the probucol-treated group than
in the other two groups.
LDL oxidizability
We compared the suppressive capacity of probucol and
atorvastatin on plasma LDL oxidization, a major insult
and trigger for atherogenesis. As shown in Figure 6, LDL
isolated from probucol-treated rabbits but not atorva-
statin-treated rabbits showed significant suppressive
ability against copper-induced oxidization expressed as a
prolonged lag-time, and decreased maximal oxidation
speed and maximal diene concentrations.
Discussion
In the current study, we compared the atheroprotective
effects of probucol and atorvastatin, two hypolipidemic
drugs for the treatment of hyperlipidemia. It is generally
believed that probucol reduces plasma cholesterol
through increasing LDL catabolism and bile excretion,
whereas atorvastatin inhibits HMG-CoA reductaseactivity and increases hepatic LDL receptor activity [14].
Here, we demonstrated that, at the optimal doses of
each drug, probucol exerts a greater inhibitory effect on
the initiation of cholesterol-diet-induced atherosclerosis
in rabbits than atorvastatin. It has been reported previ-
ously that probucol at high dose (1%) and for a long
period (2 ~ 6 months) protects against atherosclerosis in
both WHHL and cholesterol-fed rabbits [11,12]. Here,
we further demonstrated that probucol even at lower
dose (0.3%) for a short period (4 weeks) was still able to
reduce the lesions of atherosclerosis in cholesterol-fed
rabbits and the lesions were characterized by reduced in-
timal macrophage accumulation. It is interesting to note
that, unlike atorvastatin, probucol administration for a
short period did not lead to a significant cholesterol-
lowering effect, while HDL-C was significantly low.
Therefore, several possible mechanisms may operate in-
dependently upon the lipid-lowering effect regarding
probucol’s anti-atherogenic effects. First, probucol has
very strong anti-oxidative effects, whereas atorvastatin
does not. In this situation, one may consider that the
anti-atherogenic effects induced by anti-oxidation by
probucol are stronger than the lipid-lowering effects of
atorvastatin. It may also suggest that oxidation in the ar-

















Figure 5 Different intimal changes of the aorta often observed under a scanning electron microscope. (A) Normal-appearance intimal
endothelial cells. (B) Intimal surface becomes bulged without monocyte adherence (right area). (C-D) Monocytes are found under split
endothelial cells, possibly due to artifacts of the fixation and drying processes. (E-H) Monocyte adherence to the bulged or protruded intima.
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The second possible mechanism may be attributed to HDL
modulation induced by probucol. It has been reported that
HDL functions such as reverse cholesterol transport [6-8]
and anti-oxidative activity [18] are markedly up-regulated
in probucol-treated patients, while HDL-C levels are low.
If these functions occur in the arterial wall, accumulation
of lipids would be diminished. Nevertheless, these results
may raise an important question: Do we need to treat
hyperlipidemic patients with atorvastatin combined with
probucol? In Japan, probucol is used for hyperlipidemic
patients who are resistant to statins [19,20]. In China,
however, probucol is widely used for the treatment of
hyperlipidemia and given the same priority as statins. So-
called “PAS” therapy (probucol, aspirin, and statin) in
China is often prescribed for hyperlipidemic patients for
both primary and secondary prevention of coronary artery
diseases [21]. Although this question still awaits more clin-
ical investigation, apparently, the anti-oxidative capacity issuperior to the lipid-lowering effect for protection against
atherosclerosis initiation.Conclusions
Our studies provide evidence that probucol inhibited the
initiation of atherosclerosis without improving serum
TC levels, despite a lowering of serum HDL-C levels.
These results suggest that the anti-oxidative effects
exerted by probucol are more efficient and effective for
the inhibition of atherosclerosis than the cholesterol-
lowering effects.Methods
Chemicals
Probucol was synthesized at Otsuka Pharmaceutical
Co., Ltd. (Tokushima, Japan). Atorvastatin calcium




































































Figure 6 Kinetic evaluation of LDL oxidation induced by
copper. Representative kinetic graph is shown in the top panel.
Lag-time, maximal oxidization speed (V max), and maximal diene
concentration (OD max) were calculated. The values are expressed
as mean ± SEM (n = 8-9, each group). ***P < 0.001 vs. vehicle.
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Male New Zealand White rabbits (1.0-1.5 kg at age of
6-7 weeks old) provided by Kitayama Labes Co., Ltd.
(Nagano, Japan) were fed an atherogenic diet containing
0.5% cholesterol for 1 week. Using the TC levels (around
700 mg/dl), we selected those rabbits that showed a rea-
sonable response to cholesterol diet feeding for the fol-
lowing experiments. These rabbits were further fed with
either the same atherogenic diet (vehicle group) or sup-
plemented with either 0.3% (w/w) probucol or 0.005%
(w/w) atorvastatin for another 4 weeks. All diets were
prepared by Oriental Yeast Co., Ltd. (Tokyo, Japan).
Blood samples were obtained from the auricular vein
biweekly for biochemical analysis. At the end of the
experiment, all rabbits were sacrificed for evaluation of
aortic atherosclerosis. All animal experiments were
performed with the approval of the Animal Care Com-
mittee of Otsuka Pharmaceutical Company and the
University of Yamanashi.
Analysis of serum biochemistry
Serum levels of TC, TG, and HDL-C were measured using
commercial assay kits (Wako Pure Chemical Industries
Ltd., Osaka, Japan) and automated clinical analyzer
BIOLIS 24i (Tokyo Boeki Machinery, Ltd., Tokyo, Japan).Analysis of lipoproteins using HPLC
Serum lipoproteins were analyzed using HPLC (Tosoh
Co., Tokyo, Japan) according to the procedure described
by Usui et al. [22] with slight modification. In brief, sera
were separated on 2 tandem connected gel filtration
columns TSKgel LipopropakXL (Tosoh Co., Tokyo,
Japan) with phosphate-buffered saline containing 0.005%
Brij-35 and 0.05% sodium azide. The column effluent
was mixed with on-line connected cholesterol colorimet-
ric reagent (Wako Pure Chemical Industries Ltd., Osaka,
Japan) and the absorbance at 600 nm was monitored
after the enzymatic reaction in a reaction coil at 37°C.
The lipoprotein fractions of very-low-density lipoprotein,
LDL, and HDL were defined based on retention time.
Analysis of aortic atherosclerosis
At the end of the experiment, all rabbits were eutha-
nized by injection of an overdose of sodium pentobar-
bital solution. Aortas were rapidly dissected free from
the arch to the iliac artery bifurcation. The aortas were
analyzed for en face gross lesions and microscopic quan-
tification of intimal lesion areas. En face lesion area was
quantitated as described previously [23]. Aortas were
opened longitudinally and mounted on a black rubber
board, and then were photographed using a digital cam-
era. Using Photoshop software (Adobe Systems Inc., San
Jose, CA), atherosclerotic lesions were visualized first
and then quantitatively measured using the image ana-
lysis system WinRoof (Mitani Co., Tokyo, Japan). For
microscopic lesion analysis, two segments (aortic arch
and thoracic aorta) fixed in 10% formalin were embed-
ded in OCT compound (Sakura Finetek Japan Co., Ltd.,
Tokyo, Japan). Frozen sections were stained with
hematoxylin-eosin (HE) and elastica van Gieson (EVG).
The intimal lesion size was quantitatively measured
using the image analysis system WinRoof as described
previously [24]. For microscopic evaluation of the cellu-
lar components of the lesions, serial frozen sections of
the aorta were immunohistochemically stained with
RAM11 (Dako Japan Inc., Tokyo, Japan) monoclonal
antibody against rabbit macrophage using Histofine Sim-
ple Stain MAX-PO(M) kits (Nichirei Biosciences Inc.,
Tokyo, Japan). Macrophages in the lesions were mea-
sured by quantifying the positively stained area using the
image analysis system.
Scanning electron microscopic observation
To observe intimal surface changes of aorta after
cholesterol-rich diet feeding, we perfused three rabbits
from each group at the end of the experiment using
phosphate-buffered saline followed by fixative solution
containing 2.5% glutaraldehyde and 2% paraformalde-
hyde (pH 7.4) for 20 min. After that, aortas were dis-
sected free from the aortic root to the common carotid
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mens (approximately 3 mm square). These specimens
were further fixed in the same solution at 4°C overnight.
Fixed specimens were post-fixed with 1% osmium tet-
roxide (pH 7.4) and dehydrated with graded ethanol
followed by isoamyl acetate. Aortic segments were dried
in CO2 using critical point dryer HCP-2 (Hitachi Koki Co.
Ltd., Tokyo, Japan) and were sputter-coated with a thin gold
layer in an ion coater IB-3 (EIKO Co., Tokyo, Japan). The
aortic surface was examined under a scanning electron
microscope JSM-6510 (JEOL Ltd., Tokyo, Japan).
Evaluation of LDL oxidizability
Plasma LDLs (d = 1.006-1.063) were isolated by ultracen-
trifugation [25] from rabbits at 4 weeks after choles-
terol-rich-diet feeding. The susceptibility of LDL to
copper-induced oxidation was assessed by determining
the formation of conjugated dienes as described previ-
ously [26]. In brief, LDL (50 μg protein/mL) was incu-
bated with 5 μM CuSO4, and the formation of
conjugated dienes was determined by monitoring the
change of absorbance at 234 nm at 37°C with a micro-
plate reader SpectraMax 190 (Molecular Devices,
Sunnyvale, CA). Lag-time, maximal oxidization speed,
and maximal diene concentrations were calculated for
the estimation of oxidization sensitivity.
Statistical analysis
All data were expressed as mean ± SEM. Statistical sig-
nificance was determined by one-way ANOVA (Dun-
nett’s test) using SAS software (SAS Institute Japan Ltd.,
Tokyo, Japan). P values less than 0.05 were considered
significant or otherwise specified.
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